A Third-Gen EGFR-TKI Transforming Lung Cancer Treatment

　　Sunvozertinib is an innovative third-generation EGFR-tyrosine kinase inhibitor(TKI)targeting EGFR-mutated NSCLC,including sensitizing mutations(Exon 19del,L858R)and resistant mutations(T790M).Its advanced structure enhances target affinity and blood-brain barrier(BBB)penetration,addressing treatment challenges in CNS metastases and acquired resistance.Critical information is summarized below:

　　I.Administration&Dosing

　　1.Dosage and Administration

　　○Recommended dose:240mg(4×60mg tablets)orally once daily.Swallow tablets whole,with or without food.

　　○Consistency:Administer at the same time daily to maintain plasma concentration.

　　2.Dose Adjustment

　　Adjustments are made based on patient tolerance:

　　○Reduce to 180mg or 120mg daily as needed.

　　○Temporarily suspend in case of severe adverse events(AEs)and resume upon improvement.

　　3.Missed Dose Protocol

　　○If missed,take as soon as possible on the same day.

　　○If close to the next dose,skip the missed dose;do not double doses.Consult a physician for repeated misses.

　　II.Managing Common AEs

　　1.Diarrhea(common)

　　○Mild:Hydrate,adjust diet(avoid high-fiber foods).

　　○Severe:Use antidiarrheals(e.g.,loperamide)and seek medical attention for electrolyte management.

　　2.Rash(early-phase)

　　○Mild:Gentle skincare,sunscreen protection.

　　○Severe:Medical evaluation;corticosteroids if required.Avoid scratching to prevent infection.

　　3.Paronychia

　　○Prevention:Keep hands/feet clean and dry;avoid nail trauma.

　　○Treatment:Apply antibiotic ointment for mild cases;consult a doctor for severe infections.

　　4.Other AEs:Appetite loss,fatigue.Most are mild-to-moderate;severe symptoms(e.g.,dyspnea,severe abdominal pain)require immediate medical attention.

　　III.Special Population Considerations

　　●Hepatic/Renal Impairment:No adjustment for mild-to-moderate cases;use cautiously in severe impairment.

　　●Geriatric Patients:No specific dose change,but monitor closely.

　　●Pregnancy/Lactation:Contraindicated;avoid use due to fetal risk.

　　IV.Drug Interactions

　　Avoid strong CYP3A4 inhibitors(e.g.,ketoconazole)or inducers(e.g.,rifampin).Adjust doses if co-administration is necessary.Inform healthcare providers of all concurrent medications.

　　V.Efficacy Monitoring&Follow-Up

　　●Schedule regular imaging(CT/MRI)to assess tumor response.

　　●Upon disease progression,perform genetic testing to identify resistance mechanisms and guide subsequent therapies.

　　VI.Treatment Strategies&Resistance Management

　　1.Long-term Therapy:EGFR+NSCLC requires continuous targeted treatment with regular efficacy and resistance monitoring.

　　2.Overcoming Resistance:Common mechanisms include C797S mutations or bypass pathways.Post-resistance strategies may involve combination therapies or novel agents guided by genomic testing.

　　VII.Lifestyle Guidance

　　●Maintain balanced diet,moderate exercise,and adequate rest.

　　●Avoid smoking,excessive alcohol,and prolonged sun exposure.

　　●Positive mindset supports treatment adherence.